BeOne Dips on Wall Street After Cancer Results, Market Looks On
BeOne Medicines AG shares lost ground Thursday afternoon even as the biotech sector moved higher. Investors took in fresh late-stage cancer data, but enthusiasm around the company’s oncology pipeline already looked priced in. ONC slipped 2.7% to $291.98 at 2:57 p.m. EDT. The Nasdaq Biotechnology Index was up 1.1%. The gap stood out after BeOne shared a new update that came in positive on the science. Still, traders didn’t show much appetite for ONC ahead of more ASCO data due next week.